Published in Am J Psychiatry on December 01, 2006
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull (2008) 0.85
Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. Psychiatry (Edgmont) (2007) 0.78
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell (2007) 8.99
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (2013) 8.20
Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet (2007) 7.85
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet (2012) 4.59
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci (2010) 3.47
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 3.29
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr (2010) 3.09
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
Human postmortem tissue: what quality markers matter? Brain Res (2006) 2.92
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci (2010) 2.84
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2003) 2.83
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry (2012) 2.61
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry (2008) 2.53
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry (2013) 2.39
Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol Psychiatry (2012) 2.33
Conflict of interest. Am J Psychiatry (2006) 2.30
The brief negative symptom scale: psychometric properties. Schizophr Bull (2010) 2.27
The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum (2007) 2.25
Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry (2009) 2.25
Bipolar I disorder: psychopathology, medical management and dental implications. J Am Dent Assoc (2002) 2.15
Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc (2003) 2.09
Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol (2008) 2.02
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv (2007) 1.93
A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron (2011) 1.92
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
Decoding the massive genome of loblolly pine using haploid DNA and novel assembly strategies. Genome Biol (2014) 1.90
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry (2011) 1.86
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry (2012) 1.85
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) (2005) 1.82
The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol (2011) 1.82
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum (2007) 1.76
Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.76
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry (2007) 1.75
The choice of drugs for schizophrenia. N Engl J Med (2006) 1.75
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A (2005) 1.72
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med (2013) 1.70
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry (2002) 1.68
Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry (2012) 1.61
AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry (2008) 1.60
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2005) 1.58
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
Evolution of genome size and complexity in Pinus. PLoS One (2009) 1.52
Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull (2009) 1.52
Panic disorder: psychopathology, medical management and dental implications. J Am Dent Assoc (2004) 1.44
Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.43
The use of depot medications in the treatment of schizophrenia. Am J Psychiatry (2010) 1.43
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. Am J Psychiatry (2015) 1.40
Priming defense genes and metabolites in hybrid poplar by the green leaf volatile cis-3-hexenyl acetate. New Phytol (2008) 1.40
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol (2005) 1.39
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull (2010) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry (2013) 1.35
Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull (2006) 1.35
Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res (2007) 1.34
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology (2007) 1.34
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Is aberrant functional connectivity a psychosis endophenotype? A resting state functional magnetic resonance imaging study. Biol Psychiatry (2013) 1.31
Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2013) 1.30
Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2012) 1.29
Induction of activating transcription factors (ATFs) ATF2, ATF3, and ATF4 in the nucleus accumbens and their regulation of emotional behavior. J Neurosci (2008) 1.27
Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary. Neurosci Biobehav Rev (2009) 1.26
Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry (2003) 1.22
Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol (2008) 1.21
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology (2012) 1.21
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry (2009) 1.20
Reimagining psychoses: an agnostic approach to diagnosis. Schizophr Res (2013) 1.20
Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res (2011) 1.20
Serum response factor promotes resilience to chronic social stress through the induction of DeltaFosB. J Neurosci (2010) 1.19
Insight and frontal cortical function in schizophrenia: a review. Schizophr Res (2006) 1.18
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry (2002) 1.17
Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry (2005) 1.17
S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport (2007) 1.17
High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology (2009) 1.16
Regional alterations in RGS4 protein in schizophrenia. Synapse (2006) 1.15
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull (2010) 1.13
Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. Am J Psychiatry (2004) 1.13
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses (2012) 1.12